ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib

The findings emphasize the importance of targeting MEK/ERK signaling in maintaining the long-term benefit of osimertinib through overcoming acquired resistance to osimertinib, warranting further investigation of this therapeutic strategy to improve osimertinib therapeutic efficacy in the clinic.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2019-12, Vol.126 (6), p.1339-1350
Hauptverfasser: Li, Yiting, Zang, Hongjing, Qian, Guoqing, Owonikoko, Taofeek K., Ramalingam, Suresh R., Sun, Shi-Yong
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The findings emphasize the importance of targeting MEK/ERK signaling in maintaining the long-term benefit of osimertinib through overcoming acquired resistance to osimertinib, warranting further investigation of this therapeutic strategy to improve osimertinib therapeutic efficacy in the clinic.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.32655